A Phase 2 interventional study of NAC and Placebo in Huntington Disease, sponsored by Western Sydney Local Health District. Recruiting at 5 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-28.
Sponsored by Western Sydney Local Health District · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Huntington Disease with a site in Australia — 5 open to participants now, 9 under way, 3 of them phase 3. Huntington Disease · Australia.
Among the 28 studies in Huntington Disease with a site in Australia, this one is the 10th largest by planned enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2024, is one of 8 in phase 2, and was the 19th registered.
293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.
Browse Huntington Disease studies →5 of the 28 studies in Huntington Disease with a site in Australia are open now. Recruiting first, the newest first:
Sarepta Therapeutics, Inc. · Sites in Australia, New Zealand, Korea, Republic of and 2 more countries
Ages 21–70
Novartis Pharmaceuticals · Sites in Australia, United States, Argentina and 24 more countries
Ages 21–70
CHDI Foundation, Inc. · Sites in Australia, United States, Argentina and 17 more countries
Ages 18+ · Healthy volunteers
Skyhawk Therapeutics, Inc. · Sites in Australia, New Zealand
Ages 25+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 43 Huntington Disease studies recruiting now, 19 (44%) set no upper age limit and 20 (47%) stop at 75 or younger; 5 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 15 · Phase 3 9
First in 2006; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is above the median of 40 across 207 interventional studies indexed under Huntington Disease.
Median enrollment 149 across the 24 interventional studies, 2,787 across the 4 observational. Of the 18 that completed or were terminated, 14 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 28 have an industry lead sponsor. The 10 most frequent:
Western Sydney Local Health District is the lead sponsor of 36 studies on the registry; 18 are open to participants now.
Western Sydney Local Health District has 1 study filed under Huntington Disease — fewer than ten, so there is no comparison to draw.
3 of the studies in Huntington Disease with a site in Australia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06873334Phase 3Skyhawk Therapeutics, Inc.Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease | 2027-05 |
| NCT07246941Hoffmann-La RocheA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease | 2026-12-01 |
| NCT07536061Sarepta Therapeutics, Inc.A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease | 2027-11-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 28 studies in Huntington Disease with a site in Australia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
NAC-preHD is a phase II randomized placebo controlled study of oral NAC among premanifest HD gene expansion carriers, with clinical and radiological outcome at three years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1g N-Acetylcysteine capsules, taken orally twice a day.
Drug: NAC
Coated Placebo capsules, taken orally twice a day
Drug: Placebo
1g of clinical grade N-Acetylcysteine capsules, taken orally twice a day
Also known as: N-Acetylcysteine
Coated Placebo capsules, manufactured to match appearance and taste, taken orally twice a day
Caudate Atrophy Rate on volumetric MRI
Blinded assessment
Time frame: Baseline through end of study (up to 3 years)
Rate of motor phenoconversion
Defined by conversion to Diagnostic Confidence Level 4, upon blinded assessment using the UHDRS motor subscale
Time frame: Baseline through end of study (up to 3 years)
UHDRS motor subscale (total score)
Measuring changes in motor function
Time frame: Baseline through end of study (up to 3 years)
Stroop Word
Change in cognition as measured by Stroop Word
Time frame: Baseline through end of study (up to 3 years)
Trail Making Test
Change in cognition as measured by Trail Making Test
Time frame: Baseline through end study (up to 3 years)
Montreal Cognitive Assessment
Change in cognition as measured by Montreal Cognitive Assessment
Time frame: Baseline through end of study (up to 3 years)
Symbol Digit Modality Test
Change in cognition as measured by Symbol Digit Modality Test
Time frame: Baseline through end of study (up to 3 years)
Changes in Mood and Behavioural symptoms
Evaluated using the PBA-s, a semi-structured interview behavioural scale
Time frame: Baseline through end of study (up to 3 years)
Changes in Daily Function
Measured using the Total Functional Capacity and Independent Scale from the broader UHDRS and the Functional Rating Scale for HD
Time frame: Baseline through end of study (up to 3 years)
Change to Quality of Life
As measured by the standardised questionnaires, HDQoL and EQ-5D
Time frame: Baseline through end of study (up to 3 years)
Study completion (Safety and Tolerability)
Measured by the proportion of participants completing NAC arm of study
Time frame: Baseline through end of study (up to 3 years)
Incidence of abnormal laboratory values and/or 12-lead ECG changes (Safety and Tolerability)
Measured by the Number of participants with abnormal laboratory values and/or 12-lead ECG changes compared to baseline
Time frame: Baseline through end of study (up to 3 years)
Incidence of adverse and/or serious adverse events (Safety and Tolerability)
Measured by the number of adverse and/or serious adverse events
Time frame: Baseline through end of study (up to 3 years)
Plan to share: Undecided — Currently not included in ethics approval but to be investigated.
No publications or documents are linked to this record.
Started Jun 2024 (actual). Primary completion is estimated for Nov 2026, 29 months after the start.
Of 22 phase 2 interventional studies under Huntington Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 40. This study's planned 29 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acetylcysteine
Western Sydney Local Health District